Therefore, it is recommended that IGF-1 levels remain within the upper normal range (+1 to +2 SDS) for age-matched normal children during GH therapy, and it is indicated in infants and children with PWS to start therapy with a daily dose of 0.5 mg/m2 per day to minimize side effects, with subsequent adjustments toward 1.0 mg/m2 per day (117). The gene discussed is GH1; the disease is Prader-Willi syndrome.